Annovis Bio Inc. (ANVS): Price and Financial Metrics


Annovis Bio Inc. (ANVS): $12.50

-0.59 (-4.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANVS Stock Price Chart Interactive Chart >

Price chart for ANVS

ANVS Price/Volume Stats

Current price $12.50 52-week high $24.34
Prev. close $13.09 52-week low $8.39
Day low $12.28 Volume 57,500
Day high $13.20 Avg. volume 67,773
50-day MA $12.81 Dividend yield N/A
200-day MA $12.43 Market Cap 102.05M

Annovis Bio Inc. (ANVS) Company Bio


Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.


ANVS Latest News Stream


Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream


Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 16, 2022

Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments.

Yahoo | November 8, 2022

We're Not Very Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | October 26, 2022

Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in New York City.

Yahoo | October 20, 2022

Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer's Disease.

Yahoo | October 11, 2022

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo 0.16%
3-mo N/A
6-mo 15.74%
1-year -42.18%
3-year N/A
5-year N/A
YTD -28.90%
2021 133.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6247 seconds.